ClinicalTrials.gg
Not yet recruitingNCT07948408WAYWIN-301Updated Nov 19, 2026

A Phase III Study of WSD0922-FU Versus Chemotherapy In Patients With C797S+ Advanced Non-small Cell Lung Cancer

A Phase 3 interventional study of WSD0922-FU and Platinum-based doublet chemotherapy (Pemetrexed and Cisplatin or Carboplatin) in Non Small Cell Lung Cancer (NSCLC), sponsored by Wayshine Biopharm, Inc.. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Wayshine Biopharm, Inc. · Phase 3, Interventional, and Treatment

How we know

Updated Nov 19, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
196
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 1,884 studies in Carcinoma, Non-Small-Cell Lung with a site in China — 763 open to participants now, 988 under way, 203 of them phase 3. Carcinoma, Non-Small-Cell Lung · China.

Planned enrollment
531st of 1,596
196 · median 100
Started
2026
with 192 others
Phase 3
367 of 1,884
104 open now
Primary completion
2028-05
later than 748 of 987 live
Registered
1,884th of 1,884
by date

Among the 1,884 studies in Carcinoma, Non-Small-Cell Lung with a site in China, this one is the 531st largest by planned enrollment of the 1,596 interventional ones that give a count, is one of 193 that started in 2026, is one of 367 in phase 3, reaches primary completion later than 748 of the 987 other live ones, and was the 1,884th registered.

Carcinoma, Non-Small-Cell Lung

7,635 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,840 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

763 of the 1,884 studies in Carcinoma, Non-Small-Cell Lung with a site in China are open now. Recruiting first, the newest first:

758 more — sign in →

All 763 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 989 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,884 studies in Carcinoma, Non-Small-Cell Lung with a site in China, or all of them as a file.
02

Study summary

This is an Open-label, Randomized, Controlled, Multicenter Phase III Study Evaluating Efficacy and Safety of WSD0922-FU Monotherapy versus Platinum-based Doublet Chemotherapy for Participants with EGFR C797S Mutation-positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer whose Disease have Developed Resistance to Prior First-line Third-generation EGFR-TKI Therapy

03

Conditions studied

  • Non Small Cell Lung Cancer (NSCLC)

Keywords

  • WSD0922
  • WSD0922-FU
  • NSCLC
  • CNS metastasis
  • Brain metastasis
  • EGFR
  • C797S
  • Del19
  • L858R
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. or cytologically confirmed locally advanced or NSCLC
  2. Eligible for platinum-based doublet chemotherapy
  3. Prior treatment with monotherapy of third-generation EGFR-TKIs (osimertinib, Firmonertinib, Almonertinib, etc.) or third-generation EGFR-TKIs combined with anti-angiogenic drugs or Lazertinib combined with Amivantamab, confirmed by imaging evidence of disease progression, and no other systemic antitumor therapy was administered after progression
  4. Tissue sample confirmed C797S positive by central lab using NGS
  5. At least one measurable target lesion per v1.1 criteria
  6. 0-1
  7. Adequate organ function and bone marrow function
  8. Women should take appropriate measures and should not breastfeed. If they have fertility, they must undergo a negative pregnancy test before starting medication
  9. Male participants should agree to the use of contraceptive measures

Exclusion criteria

Exclusion Criteria:

  1. Presence of clear bypass tumor driver (e.g., KRAS activating mutations, Braf V600E, MET exon 14 skipping, mutations, RET fusion, ROS1 fusion etc.)
  2. Histological or phenotypic transformation
  3. Any severe or uncontrolled systemic disease
  4. ≥ Grade 2 toxicities per v6.0 attributed to prior anti-tumor therapy except hearing loss, hair loss, and fatigue
  5. Participants with , brainstem, or spinal cord and/or spinal cord compression, as well as active , increased intracranial pressure or associated risks (such as intracranial hemorrhage or intracranial infection), or symptomatic cerebral complications requiring urgent neurosurgical or pharmacological (e.g., mannitol) intervention
  6. A history of interstitial lung disease (ILD), drug-induced ILD, or non-infectious pneumonitis requiring treatment; or suspected ILD or non-infectious pneumonitis that can't be ruled out by imaging at the time of screening
  7. cardiac abnormalities or severe/uncontrolled/active cardiovascular disease
  8. Significant clinical bleeding tendency or history of severe arterial/venous thromboembolic events
  9. Poorly controlled diabetes mellitus or hypertension
  10. History of other primary within two years
  11. Known active or suspected diseases; or known active ocular diseases (such as active wet age-related macular degeneration, diabetic retinopathy with macular edema)
  12. Active infectious diseases (e.g., active , and )
  13. Known alcohol or drug dependence
  14. Mental disorders or poor compliance
  15. The investigator believes that the subject has other reasons that make them unsuitable for participating in this clinical study
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
196 participants (estimated)

Study arms

  • Experimental
    WSD0922-FU Tablet

    Drug: WSD0922-FU

  • Active comparator
    Platinum-Based Doublet Chemotherapy

    Drug: Platinum-based doublet chemotherapy (Pemetrexed and Cisplatin or Carboplatin)

Interventions

  • DrugWSD0922-FU

    Participants will take WSD0922-FU 120 mg BID under fasted condition, administered orally; treatment cycles are 21 days in duration, continuing until disease progression, occurrence of intolerable toxicity, withdrawal of informed consent, death, or fulfillment of other protocol-specified criteria for treatment discontinuation

    Also known as: WSD0922

  • DrugPlatinum-based doublet chemotherapy (Pemetrexed and Cisplatin or Carboplatin)

    Participants will receive 4 cycles of standard platinum-based doublet chemotherapy (selected by the investigator based on participant's condition and tolerance): Option 1: Pemetrexed 500 mg/m² IV infusion + Cisplatin 75 mg/m² IV infusion on Day 1 of each 21-day cycle. Option 2: Pemetrexed 500 mg/m² IV infusion + Carboplatin AUC 5 IV infusion on Day 1 of each 21-day cycle. Followed by maintenace of Pemetrexed 500 mg/m² IV infusion until disease progression, occurrence of intolerable toxicity, withdrawal of informed consent, death, or fulfillment of other protocol-specified criteria for treatment discontinuation

    Also known as: Platinum-based doublet chemotherapy, Pemetrexed, Cisplatin, Carboplatin

06

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS)

    PFS as assessed by Blinded independent Central Review (BICR) per RECIST 1.1

    Time frame: From date of randomization until the date of BICR confirmed progression or date of death from any cause, whichever comes first, assessed up to 24 months.

Secondary outcomes

  1. Overall Survival (OS)

    OS

    Time frame: From the date of randomization to the date of death from any cause, assessed up to 36 months.

Other outcomes

  1. PFS as assessed by investigator per RECIST 1.1

    Time frame: From date of randomization until the date of investigator confirmed progression or date of death from any cause, whichever comes first, assessed up to 24 months.

  2. Objective Response Rate (ORR)

    ORR as assessed by investigator and BICR per RECIST 1.1

    Time frame: From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.

  3. Duration of Response (DOR)

    DoR by BICR and Investigator per RECIST 1.1

    Time frame: From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.

  4. Disease Control Rate (DCR)

    DCR by BICR and Investigator per RECIST 1.1

    Time frame: From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.

  5. Time to Disease Progression (TTP)

    TTP by BICR and Investigator per RECIST 1.1

    Time frame: From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.

  6. Time to Response (TTR)

    TTR by BICR and Investigator per RECIST 1.1

    Time frame: From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.

  7. Intracranial ORR (icORR)

    icORR by BICR and Investigator per RANO-BM

    Time frame: From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.

  8. Intracranial PFS (icPFS)

    icPFS by BICR and Investigator per RANO-BM

    Time frame: From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.

  9. Intracranial DOR (icDOR)

    icDOR by BICR and Investigator per RANO-BM

    Time frame: From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.

  10. Intracranial DCR (icDCR)

    icDCR by BICR and Investigator per RANO-BM

    Time frame: From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.

  11. Intracranial TTP (icTTP)

    icTTP by BICR and Investigator per RANO-BM

    Time frame: From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.

  12. Intracranial TTR (icTTR)

    icTTR by BICR and Investigator per RANO-BM

    Time frame: From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.

  13. AE and SAE

    AE and SAE per CTCAE 6.0

    Time frame: From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.

  14. European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire, Core 30

    Quality of life according to the EORTC QLQ-C30 test results from a minimum of 0 to a maximum of 100, where higher scores represent either a better or worse outcome depending on the specific subscale

    Time frame: From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.

  15. European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Lung Cancer 13

    Quality of life according to the EORTC QLQ-LC13 test results from a minimum of 0 to a maximum of 100, where higher scores indicate a worse outcome

    Time frame: From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for May 2028, 16 months later.

Of 314 industry-sponsored phase 3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 57. This study's planned 16 months is below that.

Counting every sponsor, half of 423 studies reached it within 45 months; a quarter within 30 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 8, 2026
First posted
Nov 19, 2026
StartEst.
Dec 10, 2026
Primary completionEst.
May 1, 2028
CompletionEst.
Oct 31, 2029
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07948408
Lead sponsor
Wayshine Biopharm, Inc.
Responsible party
Sponsor
First posted
Nov 19, 2026
Start date
Dec 10, 2026 (estimated)
Primary completion
May 1, 2028 (estimated)
Completion
Oct 31, 2029 (estimated)
Last update
Nov 19, 2026

Study contacts

Lily Liu, MD
Contact
lily.liu@wayshinebiopharm.com
+8613818880308
Wei Zhong, PhD
Contact
wei.zhong@wayshinebiopharm.com
1-951-547-4692
Caicun Zhou, MD
principal investigator · Shanghai East Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion